Previous 10 | Next 10 |
home / stock / cslly / cslly news
CSL (OTCPK:CSLLY -4.2%) to launch an all-cash public tender offer to acquire all publicly held Vifor Pharma shares for US$179.25 per Vifor Pharma share, for an aggregate equity value for Vifor Pharma of US$11.7 / A$16.4B. Patinex AG, Vifor Pharma's largest shareholder holding 23% of Vifo...
~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec ~ ~ Etranacogene dezaparvovec also achieved seconda...
New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults PR Newswire SUMMIT, N.J. , Dec. 7, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza preventi...
Australian biotech company, CSL Limited (OTCPK:CSLLY) (OTCPK:CMXHF), is reportedly in exclusive talks to buy Vifor Pharma (OTCPK:GNHAF) (OTCPK:GNHAY) for A$10 billion ($7.10 billion), The Australian newspaper said on Thursday, according to Reuters. Swiss drugmakers’ shar...
Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine PR Newswire SUMMIT, N.J. , Nov. 23, 2021 /PRNewswire/ -- The FDA has granted approval of multi-dose vial presentation for ...
CSL Plasma Opens 300th Plasma Donation Center in United States Greenacres, Florida, center opening exemplifies growing need for plasma donations, which enable production of plasma-derived medicines for patients in 100+ countries PR Newswire BOCA RATON, Fla. , O...
Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021 PR Newswire SUMMIT, N.J. , Oct. 19, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevent...
Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D Day Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Hig...
Seqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, Expanding the Age Indication to Include Children as Young as Six Months - Approval aligns with universal age recommendation for all eligible people six months and older to receive annual influenza va...
The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to <18 Years of Age The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-...
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
CSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B Canada NewsWire The positive decision from the Canadian Agency for Drugs and Technologies in Health (CADTH) recognizes the im...
CSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season PR Newswire CSL Seqirus is the only manufacturer to offer a differentiated influenza vaccine for all eligible people aged six months and older in the United States . Centers for ...
CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza PR Newswire CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government's outbreak and preparedness response...